What is Romiplostim and How Does It Work in ITP
Romiplostim (Nplate) is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating TPO receptors on megakaryocytes, indicated for adult and pediatric ITP patients (≥1 year old with ≥6 months disease duration) who have failed corticosteroids, immunoglobulins, or splenectomy 1.
Mechanism of Action
Romiplostim is an Fc-peptide fusion protein (peptibody) that works fundamentally differently from traditional ITP therapies:
- Direct platelet production stimulation: Unlike corticosteroids or immunoglobulins that suppress immune destruction, romiplostim directly stimulates megakaryopoiesis and thrombopoiesis by activating TPO receptors 2, 3
- No sequence homology to native TPO: This design avoids the theoretical risk of generating cross-reacting neutralizing antibodies against endogenous thrombopoietin 2
- Additional immunomodulatory effects: Recent evidence suggests romiplostim may have immunomodulatory properties beyond simple platelet production 4
Clinical Positioning
Per ASH 2019 guidelines, romiplostim is recommended as a second-line option for ITP lasting ≥3 months in patients who are corticosteroid-dependent or unresponsive 5. The guidelines suggest either eltrombopag or romiplostim as TPO-RA options, with choice based on patient preference for weekly subcutaneous injections versus daily oral medication 5.
Treatment Algorithm for Second-Line ITP:
- TPO-RA (romiplostim or eltrombopag) vs. splenectomy vs. rituximab are all conditional recommendations
- TPO-RA is suggested over rituximab when comparing these two options directly 5
- Rituximab is suggested over splenectomy for patients preferring to avoid surgery 5
Dosing and Administration
Starting dose: 1 mcg/kg subcutaneously once weekly, adjusted by 1 mcg/kg increments based on platelet response (maximum 10 mcg/kg/week) 1:
- Target platelet count: ≥50 × 10⁹/L to reduce bleeding risk—not normalization of counts 1
- Dose adjustments:
- If platelets <50 × 10⁹/L: increase by 1 mcg/kg
- If platelets 200-400 × 10⁹/L for 2 weeks: reduce by 1 mcg/kg
- If platelets >400 × 10⁹/L: hold dose, resume at reduced dose when <200 × 10⁹/L
- Monitoring: Weekly CBC during dose adjustment, then monthly once stable 1
- Discontinuation criteria: If no adequate response after 4 weeks at maximum dose (10 mcg/kg) 1
Important Caveat on Initial Dosing:
Recent real-world data shows that higher initial doses (≥3 mcg/kg) do not accelerate platelet response compared to standard low-dose initiation (<3 mcg/kg), with both achieving response at median 7 days 6. Stick with the FDA-approved 1 mcg/kg starting dose.
Efficacy
Romiplostim demonstrates robust efficacy in both splenectomized and non-splenectomized patients:
- Durable platelet response: 61% in non-splenectomized vs. 38% in splenectomized patients (compared to 5% and 0% with placebo, respectively) 2, 7
- Overall response rate: 83% achieved any platelet response 7
- Time to response: Median ~2 weeks, with most patients maintaining response on median dose of 2-3 mcg/kg 1, 2
- Long-term maintenance: Real-world data shows sustained platelet counts between 10-12 × 10⁴/µL from 8-104 weeks of treatment 8
Sustained Remission After Discontinuation:
A notable finding is that 15-48% of patients maintain platelet responses after romiplostim discontinuation 9. Key observations:
- In the Newland study, 32% of recently-diagnosed ITP patients achieved remission (platelets ≥50 × 10⁹/L for 24 weeks) after romiplostim discontinuation 9
- Sustained responses maintained for median 20-33 months in various cohorts 9
- No predictive factors identified for who will maintain remission 9
Clinical implication: Consider attempting gradual taper and discontinuation once stable platelet counts achieved, with close monitoring (weekly CBC for ≥2 weeks post-discontinuation) 1.
Safety Profile
Romiplostim is generally well-tolerated with mostly mild-to-moderate adverse events 2:
Common adverse reactions (≥5% higher than placebo in adults): arthralgia, dizziness, insomnia, myalgia, extremity pain, abdominal pain, shoulder pain, dyspepsia, paresthesia, and headache 1
In pediatric patients (≥25%): contusion, upper respiratory tract infection, oropharyngeal pain 1
Critical Safety Warnings:
Contraindicated in MDS: Romiplostim increases blast counts and progression risk to acute myelogenous leukemia in myelodysplastic syndrome patients 1
Thrombotic/thromboembolic risk: Particularly concerning in chronic liver disease patients (portal vein thrombosis reported) 1
Rebound thrombocytopenia: Worsened thrombocytopenia can occur after discontinuation—requires weekly monitoring for ≥2 weeks post-stop 1
Bone marrow reticulin formation: Risk identified in FDA review 10
Neutralizing antibodies: If severe thrombocytopenia develops during treatment, assess for antibody formation 1
Real-world discontinuation rates: 14.92% discontinued due to adverse events within 2 years, while 14% discontinued due to symptom improvement 8.
Quality of Life Impact
Romiplostim significantly improves patient outcomes beyond platelet counts:
- Reduced bleeding events: Significant bleeding decreased from 76.9% to 34.6% 11
- Decreased healthcare utilization: Hospital admissions dropped from 69.2% to 7.7%, rescue medication use from 65.4% to 11.5% 11
- Improved HRQoL: Platelet counts positively correlated with health-related quality of life in pediatric patients 11
Practical Considerations
- Access: Must be ordered through manufacturer's limited access program (Risk Evaluation and Mitigation Strategy) 12, 10
- Administration: Requires clinic visits for weekly subcutaneous injections 12
- Dose precision: Very small volumes may be required—use syringes with 0.01 mL graduations 1
- Sequential TPO-RA use: Romiplostim remains effective even in patients who failed eltrombopag 11